Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.

Autor:	Mittman BG; Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Le P; Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA., Payne JY; Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA.; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Ayers G; Department of Pharmacy and Center for Geriatric Medicine, Cleveland Clinic, Cleveland, OH, USA., Rothberg MB; Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA.
Jazyk:	angličtina
Zdroj:	Current medical research and opinion [Curr Med Res Opin] 2024 Mar; Vol. 40 (3), pp. 377-383. Date of Electronic Publication: 2024 Jan 16.
DOI:	10.1080/03007995.2024.2303413
Abstrakt:	Objective: Type 2 Diabetes (T2D) is a major cause of morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are highly effective but underutilized. Our objective was to assess racial/ethnic and other sociodemographic disparities in GLP-1RA/SGLT2i use among US adults with T2D. Methods: We conducted a retrospective analysis using the National Health and Nutrition Examination Survey from 2005-March 2020. Participants were adults with T2D taking ≥1 anti-diabetic medication, excluding pregnant women and adults with probable T1D. We performed univariate analyses to examine the characteristics of patients using GLP-1RA/SGLT2i and multivariable logistic regression to assess disparities in GLP-1RA/SGLT2i use after adjusting for other patient factors. Results: Among 4777 people with T2D (representing >18 million US adults) taking ≥1 medication, GLP-1RA/SGLT2i usage increased from 1.4% in 2005-2006 to 13.3% in 2017-2020. In univariate analyses, patients using GLP-1RA/SGLT2i vs. other T2D drugs were more likely to be White than nonwhite (72% vs. 60%, p = .001), but in multivariable analysis there was no significant difference in GLP-1RA/SGLT2i use for nonwhite vs. White patients (aOR = 0.84, 95% CI [0.61, 1.16]). GLP-1RA/SGLT2i use was higher for patients who completed some college (aOR = 1.83, 95% CI [1.06, 3.15]) or above (aOR = 2.06, 95% CI [1.28, 3.32]) vs. high school or less, and for those with an income-poverty ratio ≥4 vs. <2 (aOR = 2.11, 95% CI [1.30, 3.42]). Conclusions: The use of GLP-1RA/SGLT2i drugs increased over time but remained low in March 2020. Higher education and income, but not race/ethnicity, were associated with GLP-1RA/SGLT2i use.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu